ips

(redirected from Induced Pluripotent Stem Cell)
Also found in: Medical, Acronyms, Encyclopedia, Wikipedia.
Related to Induced Pluripotent Stem Cell: in vitro

ips

abbr.
inches per second
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

ips

or i.p.s.,

inches per second.
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
References in periodicals archive ?
Maturation-based model of arrhythmogenic right ventricular dysplasia using patient-specific induced pluripotent stem cells. Circ J 2015;79:1402-8.
MSCs induced from pluripotent stem cells (PSCs), such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), could provide such a source.
Induced Pluripotent Stem Cell technology research has been diversified into multiple subgroups due to its vast applications in medicine.
Induced pluripotent stem cell intervention rescues ventricular wall motion disparity, achieving biological cardiac resynchronization post-infarction-doi: 10.1113 / jphysiol.
(1) These induced pluripotent stem cells (iPSCs) can be cultured indefinitely in the laboratory, and can undergo directed differentiation into any cell type of interest.
Since the initial description of Yamanaka and Takahashi in 2006, the generation of induced pluripotent stem cells (iPSCs) has become a widely used method [1].
"Utilizing corrected induced pluripotent stem cells to target this specific genetic disease proved effective in restoring function," said Antonio Filareto, Ph.D., a postdoctoral fellow in Perlingeiro's laboratory and the lead author on the study.
SAN DIEGO, Calif., July 24, 2018 -- University researchers have examined the whole genome sequences of 18 induced pluripotent stem cell (iPSC) lines derived from skin cells that they had reprogrammed to identify and characterize somatic mutations.
Kaufman has identified several CAR constructs optimized for NK cell signaling, persistence and cytotoxicity, and combined his targeting content with Fate Therapeutics' induced pluripotent stem cell (iPSC) product platform for development of off-the-shelf CAR-targeted NK cell products using clonal engineered master pluripotent cell lines.
The initial reprogramming focus will be on custom solutions for primary cell establishment, induced pluripotent stem cell (iPSC) generation, banking and characterization.